Please assess the completion status of the following clinical trial:

Trial Title: First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Subject will be included in the study if he meets all the following criteria:~* Healthy male born between 1979 and 1991 who has not experienced clinical pertussis (lab. Verified) during the past 10 years and who has not been vaccinated with any pertussis vaccine.~* Informed consent form signed by the subject.~* Subject shall be able to attend all scheduled visits and to understand and comply with the study procedures (e.g. able to read and write Swedish).~Exclusion Criteria:~If any of the following criteria are met, the subject must not be included in the study:~* Individuals with pertussis toxin serum IgG antibodies ≥20 units/mL.~* Blood pressure after resting ≥ 150/90 mmHg.~* Heart rate after resting ≥80 bpm.~* Respiratory rate after resting ≥ 20/minute.~* Unwillingness to refrain from the use of nicotine products from screening through day 28.~* Use of narcotic drugs/alcohol and/or a history of previous use of drug/alcohol abuse whitin the past 2 years prior to screening~* The subject has donated blood or suffered from blood loss of at least 450 ml (1 unit of blood) within 60 days prior to screening or donated plasma within 14 days prior to screening.~* Receipt of immunoglobulin, blood derived products, systemic corticosteroids or other immunosuppressant drugs within 90 days prior to day 0.~* Use of corticosteroids in the respiratory tract(e.g. nasal steroids, inhaled steroids) whitin 30 days prior to day 0.~* Use of herbal medications or dietary supplements within 7 days prior to day 0 at the discretion of the investigator. Unwillingness to refrain from herbal medications or dietary supplements within 30 days after day 0 at the discretion of the investigator.~* Receipt of a vaccine within the last 30 days prior to day 0 or planned vaccination within the next 30 days after day 0.~* Evolving encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of any vaccine.~* Known hypersensitivity to any component of the study vaccine.~* Current participation in any other clinical trial or participation (and during the whole study) in any clinical trial in the previous 3 months prior to day 0.~* Inability to adhere to the protocol, including plans to move from the area.~* Family history of congenital or hereditary immunodeficiency (first degree).~* Infection with HIV, hepatitis B or C.~* Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.~* Clinically significant abnormal laboratory values at the discretion of the investigator.~* Person in frequent contact with children less than 1 year of age (father, childcare worker, nurse, etc...) or residence in the same household as persons with known immunodeficiency.

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 31 Years
- Healthy Volunteers: t

Study Arms:
- BPZE1 - Low dose (Type: EXPERIMENTAL): 1,000 colony forming units (cfu) of BPZE1
- BPZE1- middle dose (Type: EXPERIMENTAL): 100,000 colony forming units (cfu) of BPZE1
- BPZE1 - High dose (Type: EXPERIMENTAL): 10,000,000 colony forming units (cfu) of BPZE1
- Placebo (Type: PLACEBO_COMPARATOR): Formulation buffer

Based on this trial design, predict the completion outcome and termination type (if applicable).